Wednesday, October 6, 2010

InterMune Sells Hep C Drug Rights To Roche


SAN FRANCISCO -- InterMune Inc, said late Wednesday it sold worldwide rights to its experimental Hepatitis C drug danoprevir to Roche Holding AG for $175 million cash. The sale ends a 2006 collaboration agreement between the two companies.

No comments:

Post a Comment